Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.50    0.00 (0.00%)
Bid:
13.25
Ask:
13.75
Spread: 0.50 (3.774%)
Market Cap: £65.58m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

Directorate Change

29 Jun 2009 07:00

RNS Number : 6190U
China Real Estate Opportunities PLC
29 June 2009
 



CHINA REAL ESTATE OPPORTUNITIES PLC

Board Changes

China Real Estate Opportunities plc ('"CREO" or the "Company"announces the appointment of Richard Anthony David to the Board. Mr David, aged 46, is Managing Director of Treasury Holdings China Limited and based in Shanghai. He has worked in the real estate industry since 1981 and been based in China since 1999. He joined Treasury Holdings China Limited in August 2007 having previously been Head of China Real Estate for Macquarie Bank Limited of Australia.

The Directors would also like to announce that Mr Robert Tincknell, non-executive Director of the Company, has resigned from the Board to take up a Directorship with Real Estate Opportunities plc ("REO"). Mr Tincknell was previously based in Shanghai and held the position of Managing Director in Treasury Holdings China Limited until early 2008 when he returned to the UK to take up the position of Managing Director of Treasury Holdings UK assuming operational responsibility for the UK activities of REO.

As with all appointments to the board of the Company, Mr David's appointment is subject to consent from the Jersey Regulator. Having regard to the residence of the Directors and the location of the Company's business and assets, The Panel on Takeovers and Mergers has confirmed that, upon Mr David's appointment becoming unconditionalit would no longer regard the Company as one to which the City Code on Takeovers and Mergers would apply.

Ray Horney, Chairman of CREO, commented:

"I would like to thank Rob for his contribution to the Company since its launch and welcome the appointment of Richard to the Board." 

Details of Mr David's directorships in the last five years and current directorships are detailed below:

Past directorships held within the last five years

Past directorships held within the last five years

Anting Investments Limited

Austian (Tianjin) Property Development Co Limited

China Property Investments Limited

First China Property Development Limited

First China Property Group Limited

First China Property Management Limited

Macquarie (Tianjin) Property Services Co. Ltd

Macquarie Hallway Property Limited

Macquarie Jin Lin (Mauritius) Pty Ltd

Macquarie Jin Lin Pty Limited

Macquarie Property China Pty Limited

Macquarie Real Estate Asia Limited

Markgold International Housing and Land Consulting (Beijing) Co Ltd

Markgold International Housing and Land Consulting (Shanghai) Co Ltd

Pasley International Limited

San Ling Investments Limited

Shanghai Anting Waratah Real Estate Development Co, Limited

Shanghai Chengli Properties Co Ltd

Shanghai International Company Limited

Shanghai Pdg Waratah Property Co., Ltd

Tianjin Macquarie Property Development Management Co Limited 

Current directorships

Shanghai Huatian Property Development Co., Ltd 

Shanghai Central Land Property Co., Ltd

Shanghai Vision Honest Real Estate Development Co., Ltd

Beijing Dream Land Industrial Development Co., Ltd

Beijing Treasury Industrial Development Co., Ltd

Qingdao Shangshi CREO Real Estate Co., Ltd 

Qingdao CREO Logistics Park Co., Ltd

Nanjing CREO Investment Consulting Co., Ltd

Treasury (Shanghai) Real Estate Consulting Co., Ltd

Treasury Holdings (Shanghai) Property Management Co., Ltd

Treasury Holdings China Limited Qingdao Rep. Office

Treasury Holdings Real Estate (HK) Ltd

Treasury Holdings Limited

Jagard Pty Ltd

There are no further details required to be disclosed in respect of Mr David's appointment pursuant to schedule 2(g) of the AIM rules. 

 

ENDSContact: CREORay Horney, Chairman Tel: + 44 (0)1273 775225 Sarah Moriarty, Investor Relations  Tel: +353 1 6189455 Matrix Corporate CapitalPaul Fincham Tel +44 (0) 203206 7000 DavyDes Carville Tel: +353 1 679 6363 Bankside ConsultantsSimon Rothschild, Oliver Winters Tel: + 44 (0)207 367 8888

Murray ConsultantsEd Micheau Tel: + 3531 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOABUGDLBBDGGCL
Date   Source Headline
23rd Jun 20267:00 amRNSAppointment of Nominated Adviser /Corporate Broker
4th Jun 20267:00 amRNSPosting of 2025 Annual Report and Notice of AGM
28th May 20262:35 pmRNSHolding(s) in Company
22nd May 202610:11 amRNSResult of Placing
22nd May 20267:02 amRNSProposed Placing to raise approximately £5.5m
22nd May 20267:01 amRNSFY25 Final Results
22nd May 20267:00 amRNSProposed Sale of 49% Interest in Creo Medical SL
7th May 20267:00 amRNS-RMicroBlate™ Fine commercial update
5th May 20267:00 amRNS-RSpydrBlade™ Flex used in novel BEAM procedures
30th Apr 20267:00 amRNS-RKOL presentations on Creo Core Products at DDW
29th Apr 20267:00 amRNS-RUK private hospital use Speedboat for cancer case
22nd Apr 20267:00 amRNSPositive Q1 trading update
16th Apr 20267:00 amRNSDisposal and outsourcing of manufacturing
24th Feb 20267:00 amRNSAppointment of Joint Corporate Broker
20th Jan 20267:00 amRNSFY25 Trading Update
14th Jan 20267:00 amRNSAward of Shares under Share Incentive Plan
27th Oct 20257:00 amRNSNotice of Capital Markets Day
7th Oct 202511:37 amRNSCapital Markets Day update
22nd Sep 20257:00 amRNSUnaudited results for the six months ended 30 June
12th Sep 20253:14 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSNotice of Results
12th Aug 20254:56 pmRNSDirector/PDMR Share Dealing
4th Aug 20257:00 amRNS-RSpeedboat® patient testimonial
24th Jul 20257:00 amRNSAward of Shares under SIP and Director Dealings
21st Jul 20257:00 amRNSH1’25 Trading Update
10th Jul 20257:00 amRNS-RMicroBlate™ Flex begins lung tumour clinical study
9th Jul 20259:41 amRNSPDMR Options Revision
30th Jun 20257:00 amRNSChange of Nominated Adviser
26th Jun 202511:08 amRNSResult of AGM
26th Jun 20257:00 amRNSAGM Statement and Directorate Changes
11th Jun 20257:00 amRNS-RU.S. FDA clearance for SpydrBlade™ Flex
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSPosting of AR&R and Notice of AGM
28th May 20257:00 amRNSUS Reimbursement milestone for Speedboat procedure
27th May 202512:48 pmRNSHolding(s) in Company
23rd May 20254:25 pmRNSHolding(s) in Company
22nd May 20257:00 amRNSDirectorate changes
19th May 20257:00 amRNSFinal Results
6th May 20257:00 amRNSNotice of investor presentations
15th Apr 20252:00 pmRNSNotice of Results
1st Apr 20259:34 amRNSHolding(s) in Company
31st Mar 202512:17 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSGrant of Options
20th Mar 20257:00 amRNS-RUK & EU Commercial launch of SpydrBlade™ Flex
6th Mar 20257:00 amRNSAppointment of Nominated Adviser and sole Broker
17th Feb 20257:00 amRNSFY24 Trading Update
12th Feb 202511:00 amRNSCompletion of sale of 51% interest in subsidiary
6th Feb 20259:00 amRNS-RFirst Welsh adopter of Speedboat® technology
3rd Feb 20253:00 pmRNSTotal Voting Rights
21st Jan 20257:00 amRNSAward of Shares under Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.